NCT01553071 2022-03-31Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed MalignanciesSouth Plains Oncology ConsortiumPhase 1 Terminated16 enrolled
NCT01479192 2018-11-07Fenretinide in Healthy Young Women at Genetic and Familial RiskEuropean Institute of OncologyPhase 3 Terminated20 enrolled